Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
17 08 2023
Historique:
received: 04 04 2022
accepted: 02 08 2023
medline: 21 8 2023
pubmed: 18 8 2023
entrez: 17 8 2023
Statut: epublish

Résumé

In multiple myeloma spatial differences in the subclonal architecture, molecular signatures and composition of the microenvironment remain poorly characterized. To address this shortcoming, we perform multi-region sequencing on paired random bone marrow and focal lesion samples from 17 newly diagnosed patients. Using single-cell RNA- and ATAC-seq we find a median of 6 tumor subclones per patient and unique subclones in focal lesions. Genetically identical subclones display different levels of spatial transcriptional plasticity, including nearly identical profiles and pronounced heterogeneity at different sites, which can include differential expression of immunotherapy targets, such as CD20 and CD38. Macrophages are significantly depleted in the microenvironment of focal lesions. We observe proportional changes in the T-cell repertoire but no site-specific expansion of T-cell clones in intramedullary lesions. In conclusion, our results demonstrate the relevance of considering spatial heterogeneity in multiple myeloma with potential implications for models of cell-cell interactions and disease progression.

Identifiants

pubmed: 37591845
doi: 10.1038/s41467-023-40584-4
pii: 10.1038/s41467-023-40584-4
pmc: PMC10435504
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5011

Informations de copyright

© 2023. Springer Nature Limited.

Références

Nature. 2012 May 16;486(7403):400-4
pubmed: 22722201
MAbs. 2015;7(2):311-21
pubmed: 25760767
Nucleic Acids Res. 2018 Jan 4;46(D1):D1284
pubmed: 29161433
Genet Med. 2019 Apr;21(4):972-981
pubmed: 30287923
Br J Haematol. 2012 Aug;158(3):336-46
pubmed: 22583117
Nat Commun. 2021 Nov 29;12(1):6960
pubmed: 34845188
Blood. 2016 Aug 18;128(7):959-70
pubmed: 27307294
J Biotechnol. 2017 Nov 10;261:53-62
pubmed: 28803971
Nat Genet. 2021 Mar;53(3):403-411
pubmed: 33633365
Genome Biol. 2019 Dec 31;21(1):2
pubmed: 31892342
Nat Cancer. 2020 May;1(5):493-506
pubmed: 33409501
Blood. 2018 Aug 9;132(6):587-597
pubmed: 29884741
Nat Commun. 2022 Feb 10;13(1):807
pubmed: 35145077
J Pathol. 2017 Mar;241(4):534-546
pubmed: 27976373
Blood. 2016 Jun 23;127(25):3225-36
pubmed: 27127303
Nat Biotechnol. 2021 Apr;39(4):451-461
pubmed: 32788668
Blood. 2009 Feb 26;113(9):1992-2002
pubmed: 19060246
Sci Transl Med. 2015 Apr 15;7(283):283ra54
pubmed: 25877892
Nat Methods. 2017 Sep;14(9):865-868
pubmed: 28759029
Blood. 2018 Jul 5;132(1):59-66
pubmed: 29784643
Genome Biol. 2014;15(12):550
pubmed: 25516281
Life Sci Alliance. 2023 Feb 2;6(4):
pubmed: 36732019
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Bioinformatics. 2009 Jul 15;25(14):1841-2
pubmed: 19468054
Nat Biotechnol. 2020 Mar;38(3):276-278
pubmed: 32055031
Genome Biol. 2019 Dec 23;20(1):296
pubmed: 31870423
Leukemia. 2014 Aug;28(8):1705-15
pubmed: 24480973
Nat Methods. 2019 Dec;16(12):1289-1296
pubmed: 31740819
Nucleic Acids Res. 2020 Jan 8;48(D1):D1057-D1062
pubmed: 31588507
Int J Mol Sci. 2019 Mar 12;20(5):
pubmed: 30871078
Blood. 2018 May 10;131(19):2138-2150
pubmed: 29519805
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
Bioinformatics. 2020 Feb 15;36(4):1307-1308
pubmed: 31498385
Cell. 2018 Jul 26;174(3):716-729.e27
pubmed: 29961576
Gigascience. 2021 Feb 16;10(2):
pubmed: 33590861
Cell Death Dis. 2017 Nov 2;8(11):e3161
pubmed: 29095438
JCI Insight. 2016 Dec 22;1(21):e88955
pubmed: 28018970
F1000Res. 2020 Jan 27;9:47
pubmed: 32789006
Nat Med. 2019 Jan;25(1):89-94
pubmed: 30510250
Cancer Immunol Res. 2016 Sep 2;4(9):734-43
pubmed: 27354337
Nat Biotechnol. 2019 Aug;37(8):925-936
pubmed: 31375813
Science. 2014 Jun 20;344(6190):1396-401
pubmed: 24925914
Blood. 2023 Nov 9;142(19):1633-1646
pubmed: 37390336
Nat Med. 2018 Dec;24(12):1867-1876
pubmed: 30523328
Haematologica. 2015 Mar;100(3):e110-3
pubmed: 25480495
Leukemia. 2016 Apr;30(4):951-4
pubmed: 26202926
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
Nat Rev Clin Oncol. 2022 Apr;19(4):223-236
pubmed: 35017721
Nat Biotechnol. 2019 Dec;37(12):1458-1465
pubmed: 31792411
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Cell Syst. 2019 Apr 24;8(4):281-291.e9
pubmed: 30954476
Nat Med. 2021 Apr;27(4):616-619
pubmed: 33619368
Nat Commun. 2017 Aug 16;8(1):268
pubmed: 28814763
Nat Commun. 2014;5:2997
pubmed: 24429703
Blood. 2012 Aug 2;120(5):1067-76
pubmed: 22498740
Bioinformatics. 2015 Nov 15;31(22):3718-20
pubmed: 26209431
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Immunol. 2021 Jun;22(6):769-780
pubmed: 34017122
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
Blood. 2009 Oct 22;114(17):3625-8
pubmed: 19710503
Blood. 2007 Apr 1;109(7):2708-17
pubmed: 17119115
Bioinformatics. 2017 Sep 15;33(18):2924-2929
pubmed: 28481982
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Haematologica. 2021 Oct 01;106(10):2754-2758
pubmed: 34092058
Nat Rev Cancer. 2012 Apr 12;12(5):335-48
pubmed: 22495321
Mol Syst Biol. 2019 May 22;15(5):e8339
pubmed: 31118277
Oncotarget. 2014 Nov 30;5(22):11283-96
pubmed: 25526031
Nat Med. 2021 Mar;27(3):491-503
pubmed: 33619369
Blood. 2011 Dec 1;118(23):5989-95
pubmed: 21900189

Auteurs

Lukas John (L)

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Alexandra M Poos (AM)

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Alexander Brobeil (A)

Department of Pathology, Heidelberg University Hospital, Heidelberg, Germany.

Carolina Schinke (C)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Stefanie Huhn (S)

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.

Nina Prokoph (N)

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Raphael Lutz (R)

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.

Barbara Wagner (B)

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.

Maurizio Zangari (M)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Stephan M Tirier (SM)

Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany.

Jan-Philipp Mallm (JP)

Single Cell Open Lab, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany.

Sabrina Schumacher (S)

Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany.

Dominik Vonficht (D)

Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.

Llorenç Solé-Boldo (L)

Institute of Health (BIH) at Charité-Universitätsmedizin Berlin, Berlin, Germany.
Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany.

Sabine Quick (S)

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.

Simon Steiger (S)

Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany.

Moritz J Przybilla (MJ)

Division Computational Genomics and Systems Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Wellcome Sanger Institute, Wellcome Trust Genome Campus, Cambridge, UK.

Katharina Bauer (K)

Single Cell Open Lab, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany.

Anja Baumann (A)

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Stefan Hemmer (S)

Department of Orthopedic Surgery, Heidelberg University Hospital, Heidelberg, Germany.

Christoph Rehnitz (C)

Department of Radiology, Heidelberg University Hospital, Heidelberg, Germany.

Christian Lückerath (C)

Department of Radiology, Heidelberg University Hospital, Heidelberg, Germany.

Christos Sachpekidis (C)

Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Gunhild Mechtersheimer (G)

Department of Pathology, Heidelberg University Hospital, Heidelberg, Germany.

Uwe Haberkorn (U)

Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.

Antonia Dimitrakopoulou-Strauss (A)

Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Philipp Reichert (P)

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.

Bart Barlogie (B)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Carsten Müller-Tidow (C)

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Heidelberg, Germany.

Hartmut Goldschmidt (H)

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Heidelberg, Germany.

Jens Hillengass (J)

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Leo Rasche (L)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Department of Internal Medicine 2, University Hospital of Würzburg, Würzburg, Germany.
Mildred Scheel Early Career Center (MSNZ), University Hospital of Würzburg, Würzburg, Germany.

Simon F Haas (SF)

Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
Institute of Health (BIH) at Charité-Universitätsmedizin Berlin, Berlin, Germany.
Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany.

Frits van Rhee (F)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Karsten Rippe (K)

Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany.

Marc S Raab (MS)

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Sandra Sauer (S)

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.

Niels Weinhold (N)

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany. niels.weinhold@med.uni-heidelberg.de.
Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. niels.weinhold@med.uni-heidelberg.de.
Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA. niels.weinhold@med.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH